Patents Assigned to D-Pharm Ltd.
-
Patent number: 8507436Abstract: The present invention relates to isolated 18-mer peptides corresponding to amino acid residues 369-386 of human plasminogen activator inhibitor 1 (PAI-1) and fragments thereof, compositions that include such peptides, and uses of such compositions for treating thromboembolic diseases and pathological conditions associated with neurological damage.Type: GrantFiled: July 24, 2008Date of Patent: August 13, 2013Assignee: D-Pharm Ltd.Inventor: Abd Al-Roof Higazi
-
Publication number: 20110105607Abstract: The present invention relates to the use of lipophilic diesters of the chelating agent 1,2-bis(2 aminophenoxy)ethane-N,N,N?,N?-tetraacetic acid (BAPTA) for inhibition of proteolytic activities of certain metalloproteinases, calpain and TACE The invention further relates to methods for preventing, treating or managing TACE-related diseases or disorders in mammals comprising administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of said lipophilic diesters of the chelating agent BAPTA.Type: ApplicationFiled: August 12, 2010Publication date: May 5, 2011Applicant: D-PHARM Ltd.Inventors: Sarina STRIEM, Jonathan Eduard Friedman, Dalia Reznitsky-Cohen, Alexander Kozak
-
Patent number: 7799831Abstract: The present invention relates to the use of lipophilic diesters of the chelating agent 1,2-bis(2 aminophenoxy)ethane-N,N,N?,N?-tetraacetic acid (BAPTA) for inhibition of proteolytic activities of certain metalloproteinases and of calpain. The invention further relates to methods for preventing, treating or managing MMP-related and calpain-related diseases or disorders in mammals comprising administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of said lipophilic diesters of the chelating agent BAPTA.Type: GrantFiled: March 16, 2003Date of Patent: September 21, 2010Assignee: D-Pharm Ltd.Inventors: Sarina Striem, Jonathan Eduard Friedman, Dalia Reznitsky-Cohen, Alexander Kozak
-
Patent number: 7745426Abstract: The present invention relates to compounds and compositions useful for reducing the risk of epileptic occurrences and/or for alleviating epileptic phenomena in patients. In accordance with the invention, the compounds and compositions have at least the following two components: a) vitamin B6-based component selected from pyridoxal, pyridoxamine, pyridoxine, their pharmaceutically acceptable functional derivatives and salts; and b) at least one antiepileptic drug (AED) or anticonvulsive, neuro-protective drug or nootrope compound or moiety. The invention further relates to methods for preventing epileptic episodes and for alleviating epileptic episodes, as well as methods for reducing side effects of antiepileptic drugs.Type: GrantFiled: August 12, 2004Date of Patent: June 29, 2010Assignees: D-Pharm Ltd., Advanced Neuroprotective Systems Ltd.Inventors: Svetlana Dolina, Vitaly Shteiman, Marina Vinnikova, Israel Shapiro
-
Patent number: 7687483Abstract: Novel phospho-derivatives of branched-chain lipophilic molecules useful for permeabilizing biological barriers and for inhibiting tumor growth are disclosed. Pharmaceutical compositions comprising phospho-derivatives of branched-chain lipophilic molecules and their uses are also disclosed.Type: GrantFiled: January 11, 2007Date of Patent: March 30, 2010Assignee: D-Pharm Ltd.Inventors: Alexander Kozak, Marina Vinnikova, Michael Polyak, Eliezer Beit-Yannai, Dalia Reznitsky-Cohen, Alexander Senderikhin
-
Patent number: 7417035Abstract: Disclosed are compounds having non-steroidal anti-inflammatory drugs (NSAIDS) covalently linked to a phospholipid moiety via a bridging group. Also disclosed are a process for the synthesis of the compounds, pharmaceutical compositions comprising the compounds and the use thereof for the treatment of diseases and disorders related to inflammatory conditions.Type: GrantFiled: December 20, 2006Date of Patent: August 26, 2008Assignee: D-Pharm Ltd.Inventors: Alexander Kozak, Israel Shapiro
-
Publication number: 20070191310Abstract: Disclosed are compounds having non-steroidal anti-inflammatory drugs (NSAIDS) covalently linked to a phospholipid moiety via a bridging group. Also disclosed are a process for the synthesis of the compounds, pharmaceutical compositions comprising the compounds and the use thereof for the treatment of diseases and disorders related to inflammatory conditions, such as the treatment of ischemia.Type: ApplicationFiled: December 20, 2006Publication date: August 16, 2007Applicant: D-Pharm, Ltd.Inventors: Alexander Kozak, Israel Shapiro
-
Publication number: 20070135381Abstract: Novel phospho-derivatives of branched-chain lipophilic molecules useful for permeabilizing biological barriers and for inhibiting tumor growth are disclosed. Pharmaceutical compositions comprising said molecules and their uses are also disclosed.Type: ApplicationFiled: January 11, 2007Publication date: June 14, 2007Applicant: D-PHARM LTD.Inventors: Alexander Kozak, Marina Vinnikova, Michael Polyak, Eliezer Beit-Yannai, Dalia Reznisky-Cohen, Alexander Senderikhin
-
Patent number: 7186703Abstract: The present invention discloses novel phospho-derivatives of branched-chain lipophilic molecules useful for permeabilizing biological barriers and for inhibiting tumor growth. The invention further discloses pharmaceutical compositions comprising said molecules and their uses.Type: GrantFiled: August 1, 2001Date of Patent: March 6, 2007Assignee: D-Pharm Ltd.Inventors: Alexander Kozak, Marina Vinnikova, Michael Polyak, Eliezer Beit-Yannai, Dalia Reznitsky-Cohen, Alexander Senderikhin
-
Patent number: 7173018Abstract: Disclosed are compounds having non-steroidal anti-inflammatory drugs (NSAIDS) covalently linked to a phospholipid moiety via a bridging group. Also disclosed are a process for the synthesis of the compounds, pharmaceutical compositions comprising the compounds and the use thereof for the treatment of diseases and disorders related to inflammatory conditions, such as the treatment of ischemia.Type: GrantFiled: January 14, 2004Date of Patent: February 6, 2007Assignee: D-Pharm, Ltd.Inventors: Alexander Kozak, Israel Shapiro
-
Publication number: 20060235000Abstract: The present invention relates to compounds and compositions useful for reducing the risk of epileptic occurrences and/or for alleviating epileptic phenomena in patients. In accordance with the invention, the compounds and compositions have at least the following two components: a) vitamin B6-based component selected from pyridoxal, pyridoxamine, pyridoxine, their pharmaceutically acceptable functional derivatives and salts; and b) at least one antiepileptic drug (AED) or anticonvulsive, neuro-protective drug or nootrope compound or moiety. The invention further relates to methods for preventing epileptic episodes and for alleviating epileptic episodes, as well as methods for reducing side effects of antiepileptic drugs.Type: ApplicationFiled: August 12, 2004Publication date: October 19, 2006Applicants: D-PHARM Ltd., Advanced Neuroprotective Systems Ltd.Inventors: Svetlana Dolina, Vitaly Shteiman, Marina Vinnikova, Israel Shapiro
-
Publication number: 20060167092Abstract: The present invention relates to the use of lipophilic diesters of the chelating agent 1,2-bis(2 aminophenoxy)ethane-N,N,N?,N?-tetraacetic acid (BAPTA) for inhibition of proteolytic activities of certain metalloproteinases and of calpain. The invention further relates to methods for preventing, treating or managing MMP-related and calpain-related diseases or disorders in mammals comprising administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of said lipophilic diesters of the chelating agent BAPTA.Type: ApplicationFiled: March 16, 2003Publication date: July 27, 2006Applicant: D-Pharm LtdInventors: Sarina Striem, Jonathan Friedman, Dalia Reznitsky-Cohen, Alexander Kozak
-
Patent number: 6774121Abstract: The invention discloses prodrugs comprising anti-proliferative drugs covalently linked, via bridging group, to a phospholipid moiety such that the active species is preferentially released, preferably by enzymatic cleavage, at the required site of action. The invention further discloses pharmaceutical compositions said prodrugs and the uses thereof for the treatment of diseases and disorders related to inflammatory, to degenerative or atrophic conditions, and to uncontrolled cell growth. FIG. 1 depicts a graph of animal survival during the course of an experiment wherein mice were i.p. transplanted with 11210 mouse leukemia cells and then treated with vehicle only (squares), MTX (triangles) or molar equivalent dose of DP-MTX071 (circles) according to the regiment described example in Example 11.Type: GrantFiled: March 13, 2002Date of Patent: August 10, 2004Assignee: D-Pharm, Ltd.Inventors: Alexander Kozak, Israel Shapiro, Marina Vinnikova, Leonid Ershov, Alexander Senderikhin, Oran Ayalon
-
Publication number: 20040147485Abstract: Disclosed are compounds having non-steroidal anti-inflammatory drugs (NSAIDS) covalently linked to a phospholipid moiety via a bridging group. Also disclosed are a process for the synthesis of the compounds, pharmaceutical compositions comprising the compounds and the use thereof for the treatment of diseases and disorders related to inflammatory conditions, such as the treatment of ischemia.Type: ApplicationFiled: January 14, 2004Publication date: July 29, 2004Applicant: D-Pharm, Ltd.Inventors: Alexander Kozak, Israel Shapiro
-
Patent number: 6730696Abstract: Disclosed are compounds having non-steroidal anti-inflammatory drugs (NSAIDS) covalently linked to a phospholipid moiety via a bridging group. Also disclosed are a process for the synthesis of the compounds, pharmaceutical compositions comprising the compounds and the use thereof for the treatment of diseases and disorders related to inflammatory conditions, such as the treatment of ischemia.Type: GrantFiled: May 16, 2001Date of Patent: May 4, 2004Assignee: D-Pharm, Ltd.Inventors: Alexander Kozak, Israel Shapiro
-
Patent number: 6518311Abstract: The present invention relates to compounds and pharmaceutical compositions useful for treating pain. The invention also relates to methods of treating or alleviating pain in mammals, comprising administering to a mammal suffering from pain, a pain-alleviating amount of a compound of the general formula (I) or (II).Type: GrantFiled: June 25, 2001Date of Patent: February 11, 2003Assignee: D-Pharm Ltd.Inventors: Alexander Kozak, Revital Duvdevani, Firas M. Younis
-
Patent number: 6458837Abstract: The invention discloses stable diesters of chelating agents of divalent metal ions, processes for their preparation and pharmaceutical compositions thereof. Most preferred compounds according to the present invention are stable lipophilic diesters comprising a covalent conjugate of a BAPTA and a pharmaceutically acceptable alcohol. The diesters are useful in a method for treating a condition or disease related to an excess of divalent metal ions, and in particular for the treatment of a condition or disease related to elevated levels of intracellular calcium ions, such as in brain or cardiac ischemia, stroke, epilepsy, Alzheimer's disease or cardiac arrhythmia and in open heart surgery.Type: GrantFiled: March 27, 2000Date of Patent: October 1, 2002Assignee: D-Pharm Ltd.Inventors: Alexander Kozak, Israel Shapiro
-
Patent number: 6413949Abstract: The invention relates to a pharmaceutically acceptable prodrug which is a covalent conjugate of a pharmacologically active compound and an intracellular transporting adjuvant, characterized by the presence of a covalent bond which is scission-sensitive to intracellular enzyme activity. The prodrug may be used in a technique for treating a condition or disease in a mammal related to supranormal intracellular enzyme activity, whereby on administering it to a human having such condition or disease, the bond is broken in response to such activity, and the pharmacologically active compound is activated selectively within cells having such supranormal intracellular enzyme activity.Type: GrantFiled: June 7, 1995Date of Patent: July 2, 2002Assignee: D-Pharm, Ltd.Inventor: Alexander Kozak
-
Publication number: 20020042445Abstract: The present invention relates to compounds and pharmaceutical compositions useful for treating pain. The invention also relates to methods of treating or alleviating pain in mammals, comprising administering to a mammal suffering from pain, a pain-alleviating amount of a compound of the general formula (I) or (II).Type: ApplicationFiled: June 25, 2001Publication date: April 11, 2002Applicant: D-Pharm LTD.Inventors: Alexander Kozak, Revital Duvdevani, Firas M. Younis
-
Patent number: 6355629Abstract: The invention relates to a pharmaceutically acceptable prodrug which is a covalent conjugate of a pharmacologically active compound and an intracellular transporting adjuvant, characterized by the presence of a covalent bond which is scission-sensitive to intracellular enzyme activity. The prodrug may be used in a technique for treating a condition or disease in a mammal related to supranormal intracellular enzyme activity, whereby on administering it to a human having such condition or disease, the bond is broken in response to such activity, and the pharmacologically active compound is activated selectively within cells having such supranormal intracellular enzyme activity.Type: GrantFiled: February 6, 2001Date of Patent: March 12, 2002Assignee: D-Pharm Ltd.Inventor: Alexander Kozak